Prenatal Testing During the Third Trimester

Key Points

• Third-trimester testing assesses ongoing fetal well-being and guides timing of delivery.
• Common tools include ultrasound growth/placenta assessment, NST, BPP, AFI, and movement counts.
• Nonreassuring results often trigger stepwise escalation to additional testing or delivery planning.
• Nursing care emphasizes preparation, interpretation support, and urgent escalation readiness.

Pathophysiology

In late pregnancy, placental reserve and uteroplacental perfusion determine fetal oxygenation and growth. Antepartum testing evaluates whether fetal compensation remains adequate or deterioration is developing. Third-trimester ultrasound is typically performed from about 28 weeks onward when growth, presentation, placental status, or amniotic-fluid concerns require clarification.

Reduced movement, nonreactive heart-rate patterns, oligohydramnios, and abnormal biophysical findings can indicate hypoxic risk, placental insufficiency, or other high-acuity conditions requiring rapid intervention. Fetal movement counting is a practical first-line surveillance strategy in late pregnancy; abnormal movement patterns commonly trigger formal NST/BPP pathways. If third-trimester ultrasound findings are unclear in suspected complex anomalies (for example central nervous system, face/neck, thoracic, or abdominal pathways), fetal MRI may be used as adjunct imaging for better anatomic definition. When non-emergency early delivery is being considered before about 38 weeks, third-trimester amniocentesis may be used for fetal lung-maturity assessment (for example lecithin/sphingomyelin ratio context) to reduce neonatal respiratory-distress risk.

Classification

• Ultrasound surveillance domain: Growth trends, placental location, amniotic-fluid assessment, and presentation.
• Heart-rate surveillance domain: NST (commonly from about 28 weeks when indicated) and vibroacoustic stimulation response.
• Composite surveillance domain: BPP and AFI scoring.
• Escalation domain: CST interpretation or delivery-planning pathways for persistent nonreassurance.
• Adjunct imaging domain: Fetal MRI when ultrasound characterization is limited.
• Diagnostic maturation domain: Third-trimester amniocentesis for selected fetal-well-being or lung-maturity decision pathways.

Nursing Assessment

NCLEX Focus

Compare fetal status trends over time; single reassuring snapshots do not replace pattern surveillance.

• Assess indication for testing and maternal symptom context.
• In third-trimester ultrasound planning, verify indication clusters such as growth/date discordance, abnormal bleeding or pain, decreased fetal movement, suspected placental disorders (for example previa/accreta/abruption), membrane rupture, or preterm-labor concern.
• For NST pathways, verify high-yield indication groups such as decreased fetal movement, postdates pregnancy, chronic maternal disease (for example hypertension, diabetes, cardiac disease, clotting disorders), multiple gestation, or prior adverse pregnancy history.
• Verify fetal movement pattern and daily count understanding (including threshold of at least 10 movements in 2 hours).
• Monitor tracing quality and response criteria during NST/CST workflows.
• For NST planning, verify gestational age and indication because testing is commonly initiated from about 28 weeks in high-risk or concern-driven pathways.
• Interpret NST outcomes using gestational-age criteria: at or above 32 weeks, at least two accelerations of 15 bpm for 15 seconds in 20 minutes; below 32 weeks, 10 bpm for 10 seconds.
• If NST remains nonreactive over a 20- to 40-minute observation period, assess reversible causes (for example fetal sleep state or medication effects) and escalate per protocol.
• Identify maternal factors affecting interpretation (medications, sleep cycle, glucose status).
• Evaluate BPP and AFI interpretation thresholds: BPP 8 to 10 reassuring, 6 repeat/close follow-up, 2 to 4 nonreassuring, and 0 critical concern; AFI commonly normal at about 5 to 25 cm with deepest vertical pocket greater than 2 cm.
• For BPP pathways in high-risk pregnancy, verify expected start timing near 32 weeks in many protocols, with earlier initiation when severe or multiple risk conditions are present.
• For third-trimester amniocentesis pathways, verify indication (often lung-maturity decision support before potential preterm delivery), baseline maternal-fetal status, and patient understanding of invasive-risk tradeoffs.
• Escalate promptly for persistent nonreassuring findings.

Nursing Interventions

• Educate on why each surveillance test is ordered and what results mean.
• Prepare patient positioning/comfort and reduce anxiety during testing.
• Implement protocol-driven escalation after nonreactive or abnormal results.
• Reinforce home instructions for fetal movement count and triage triggers: choose active period, count fetal movements in side-lying or relaxed position, and escalate if movement threshold is not reached after supportive measures.
• During NST workflows, reinforce button-use teaching for maternal perception of fetal movement and explain that additional stimulation (for example vibroacoustic stimulation) may be used if fetal sleep is suspected.
• Explain vibroacoustic testing as a brief abdominal sound-vibration stimulus intended to provoke fetal movement and heart-rate acceleration; absence of expected response is nonreassuring and commonly triggers additional testing.
• If NST remains nonreactive, reinforce common immediate reassessment steps (for example maternal snack or glucose intake when appropriate and extended observation up to about 40 minutes) before final escalation decisions.
• Explain AFI-related counseling in plain language, including implications of persistent oligohydramnios or polyhydramnios for ongoing surveillance and delivery planning.
• Explain that BPP is commonly integrated with NST and AFI scoring and may be repeated within 24 hours after equivocal results.
• For CST preparation, explain that it is often reserved for selected pathways (for example persistent nonreactive NST when BPP ultrasound is not immediately available), and that contractions may be induced with oxytocin or nipple stimulation to reach a target pattern (about 3 contractions in 10 minutes, each lasting at least 40 seconds).
• Reinforce CST interpretation language used in practice: negative (no late/variable decelerations), positive (late decelerations after contractions), equivocal-suspicious (intermittent concerning decelerations), equivocal-hyperstimulation context, and unsatisfactory tracing.
• If CST is performed, obtain baseline tracing before stimulation and continue fetal heart-rate surveillance after testing while provider plan is finalized.
• If fetal MRI is ordered after unclear ultrasound findings, provide plain-language preparation teaching and explain that results are used to refine risk counseling and delivery/newborn-care planning.
• If third-trimester amniocentesis is ordered, reinforce informed-consent quality and teach urgent postprocedure warnings (persistent pain, bleeding, fluid leakage, fever, or decreased fetal movement).
• Coordinate follow-up schedule and multidisciplinary planning if risk increases.

Reassurance Delay

Waiting too long after repeated nonreassuring fetal surveillance can increase risk of preventable hypoxic injury.

Pharmacology

Drug Class	Examples	Key Nursing Considerations
corticosteroids (antenatal-corticosteroids)	Imminent preterm-delivery contexts	Supports fetal lung maturation when early delivery risk is high.
preeclampsia (antihypertensives-in-pregnancy)	Hypertensive-complication contexts	Maternal stabilization often improves fetal surveillance reliability and safety.

Clinical Judgment Application

Clinical Scenario

A 34-week patient with hypertension has a nonreactive NST, reduced movement report, and low AFI.

• Recognize Cues: Multiple nonreassuring fetal-status indicators.
• Analyze Cues: Pattern suggests uteroplacental compromise risk.
• Prioritize Hypotheses: Priority is urgent maternal-fetal reassessment and escalation.
• Generate Solutions: Perform protocol escalation (BPP/CST as indicated) and notify obstetric team.
• Take Action: Initiate continuous monitoring and delivery-readiness planning.
• Evaluate Outcomes: Timely intervention prevents progression to severe fetal compromise.

Related Concepts

• care-in-the-third-trimester-of-pregnancy - Routine third-trimester visits identify candidates for enhanced testing.
• conditions-limited-to-pregnancy - Hypertensive/placental disorders are common triggers for surveillance.
• fetal-growth-and-development - Growth and placental dynamics underlie test interpretation.
• choosing-a-birthing-place - Surveillance outcomes may change recommended delivery setting.
• person-and-family-centered-care - Communication around nonreassuring tests requires clear shared planning.

Self-Check

1. What differentiates a reactive from nonreactive NST?
2. How should care escalate after combined abnormal NST and low AFI?
3. Which teaching points improve reliability of home fetal movement counts?